FDA Warns Sanofi Over 'Misleading' Uroxatral Ads
The U.S. Food and Drug Administration has warned drugmaker Sanofi-Aventis that a promotional advertisement for its prostate treatment Uroxatral misbrands the drug, in violation of the Federal Food, Drug and Cosmetic...To view the full article, register now.
Already a subscriber? Click here to view full article